Is ICP all you need to know?



Codman®
SPECIALTY SURGICAL
A DIVISION OF INTEGRA LIFESCIENCES

Licox® Brain Tissue Oxygen
Monitoring Solution

Missing clinically significant events

47%

of severe TBI patients with normal CPP & ICP may have cerebral hypoxia[1]



Only ICP Monitoring = 3X more time experiencing Hypoxia* & trend towards higher mortality**

BOOST II[2] is a multicentre, single-blind, prospective, Randomized, controlled trial in severe TBI neuromonitoring.

R

ICP/P_tO_2 group (n=57)

ICP control group (n=62)

Results - Glasgow Outcome Scale extended at 6 months



Patients may suffer from irreversible secondary brain injury.

*This number is derived from Proportion of time below 20 mmHg results from page 1912 of the BOOST II publication. ICP- group mean was 44% and for ICP/P_tO_2-group was 15% -> 44%/15% = 2.9 times more ~3, highly significant with p=0.0000147

** Results are based on 6 months GOS-E - Glasgow Outcome Scale extended

Licox® Brain Tissue Oxygen Monitoring Solution

Introducing P_tO_2-monitoring in TBI treatment protocols may reduce mortality by up to 57%[3]



Manage hypoxic events effectively using Licox® P_tO_2 monitoring and a tailored education program.

MULTIMODALITY
NEUROMONITORING
CENTRE OF EXCELLENCE

Global Neuro

EDUCATION MATTERS

Licox® Brain Tissue Oxygen Monitoring Solution

ICP monitoring is currently the standard practice for managing severe TBI patients.

However, 47% of patients suffer from hypoxia while ICP and CPP are unsuspicious.[1]

Changing your TBI protocol to include Licox® P_tO_2 monitoring will help manage hypoxic events effectively and avoid unnecessary brain injuries.

Availability of these products might vary from a given country or region to another, as a result of specific local regulatory approval or clearance requirements for sale in such country or region.
- Non contractual document. The manufacturer reserves the right, without prior notice, to modify the products in order to improve their quality.
- Warning: Applicable laws restrict these products to sale by or on the order of a physician.
- Consult product labels and inserts for any indications, contraindications, hazards, warnings, precautions, and instructions for use.

Products mentioned in this document are CE class I, IIa, IIb & III devices. Please contact Integra customer service should you need any additional information on devices classification. All the medical devices mentioned on this document are CE marked according to European council directive 93/42/EEC on medical devices and its relatives, unless specifically identified as "NOT CE MARKED".

For more information or to place an order, please contact:

Sales & Marketing EMEA
Integra LifeSciences Services (France) SAS
Immeuble Séquoia 2 ▪ 97 allée Alexandre Borodine
Parc technologique de la Porte des Alpes
69800 Saint Priest ▪ France
Phone: +33 (0)4 37 47 59 00 ▪ +33 (0)4 37 47 59 99 (fax)
integralife.eu

Integra Contact - Questions, Information & Product Ordering
International: +33 (0)437 47 59 50 ▪ +33 (0)437 47 59 25 (Fax) ▪ csemea@integralife.com
Austria: +43 (0)720816067 ▪ +43 (0)19287201 (Fax)▪ custsvcaustria@integralife.com
Belgium & Luxembourg: +32 (0)2 257 4130 ▪ +32 (0)2 253 2466 (Fax) ▪ custsvcbenelux@integralife.com
Germany: +49 (0)2102 5535 6200 ▪ +49 (0)2102 5536 636 (Fax) ▪ custsvcgermany@integralife.com
Ireland: +353 1800 901567 ▪ +353 1822 5952 (Fax) ▪ custsvcire@integralife.com
Italy: +39 (0)2 577 89 21 ▪ +39 (0)2 575 113 71 (Fax) ▪ custsvcitaly@integralife.com
Netherlands: +31 (0)852083167 ▪ +31 (0)207093627 (Fax) ▪ custsvcnetherlands@integralife.com
Switzerland: +41 (0)2 27 21 23 00 ▪ +41 (0)2 27 21 23 99 (Fax) ▪ custsvcsuisse@integralife.com
United Kingdom: +44 (0)1264 312 725 ▪ +44 (0)1264 312 821 (Fax) ▪ custsvcs.uk@integralife.com
France: +33 (0) 437 47 59 10 ▪ +33 (0) 437 47 59 29 (Fax) ▪ custservfrance@integralife.com

CE 2797 Licox® Probes, introducers and kits:
Integra NeuroSciences Implants (France) S.A.S.
2905, route des Dolines
06921 Sophia Antipolis CEDEX ▪ France

CE 2797 LCX02:
Integra LifeSciences (Ireland) Ltd,
IDA Business and Technology Park
Sragh, Tullamore, County Offaly ▪ Ireland

CE 2797 Integra LifeSciences Production Corporation
11 Cabot Boulevard
Mansfield, MA 02048 ▪ USA

EC REP Integra LifeSciences Services (France)
Immeuble Séquoia 2 ▪ 97 allée Alexandre
Borodine Parc technologique de la Porte des Alpes
69800 Saint Priest ▪ France

INTEGRA® LIMIT UNCERTAINTY

Licox® Brain Tissue Oxygen Monitoring Solution

Ordering Information:

Product Code	Description	Picture
LCX02	Licox® P_tO_2 Monitor	
IM2SEU	Double Lumen Brain Probe Kit with P_tO_2 probe,	
IM3STEU	Triple Lumen Brain Probe Kit	
IT2EU	LICOX® Complete Brain Tunneling Probe Kit	

Licox® P_tO_2 Monitor Technical specifications[4]	
Size: H 165 mm x W 240 mm x D 185 mm	Screen Diagonale: 18 cm TFT LCD
Weight: 3 Kg	Battery Autonomy: 1,5 h

ICP sensor for multimodal monitoring		
626631	Codman Microsensor® Basic Kit compatible with IM3STEU or IM2SEU	

Indications For Use the Integra Licox® P_tO_2 Monitor:

The Integra Licox® P_tO_2 Monitor measures oxygen partial pressure (P_tO_2) and temperature in brain tissue and these parameters are used together as an aid in the determination of the perfusion status of cerebral tissue local to sensor placement.Monitor values are relative within an individual, and should not be used as the sole basis for determining a diagnosis or therapy. It is intended to provide data additional to that obtained by current clinical practice in cases where hypoxia or ischemia are a concern.

Contraindications the Integra Licox® P_tO_2 Monitor:

The Integra Licox® P_tO_2 Monitor and its accessories are contraindicated for use in a Magnetic Resonance (MR) environment.

Indications For Use - the Licox Brain Oxygen Monitoring System (IM3STEU, IM2SEU, IP1P):

The Licox Brain Oxygen Monitoring System measures intracranial oxygen and temperature and is intended as an adjunct monitor of trends of these parameters, indicating the perfusion status of cerebral tissue local to sensor placement. Licox System values are relative within an individual, and should not be used as the sole basis for decisions as to diagnosis or therapy. It is intended to provide data additional to that obtained by current clinical practice in cases where hypoxia or ischemia are a concern.

Contraindications - the Licox Brain Oxygen Monitoring System (IM3STEU, IM2SEU, IP1P):

Licox products are not intended for any use other than that indicated. Contraindications for device insertion into the body apply, e.g. coagulopathy and/or susceptibility to infections or infected tissue. A platelet count of less than 50 000 per µl is considered a contraindication. This value may differ according to different hospital Protocols.

Indications - Codman Microsensor® basic kit (626631):

Use of the CODMAN MICROSENSOR Basic Kit is indicated when direct ICP monitoring is required. The kit is indicated for use in both subdural and intraparenchymal pressure monitoring applications only. The technical performance characteristics of the CODMAN MICROSENSOR have been evaluated for a maximum monitoring period of up to 30 days. Use clinical judgment to determine the implantation time of this product based on experience and consideration of any other relevant clinical factors.

Contraindications - Codman Microsensor® basic kit (626631):

This kit is not designed, sold, or intended for any use except as indicated. This kit is not designed, sold, or intended for use as a therapeutic device.

1. Stiefel et al, Conventional neurocritical care and cerebral oxygenation after traumatic brain injury.J Neurosurg 105:568–575, 2006
2. Okonkwo et al. ; Brain Oxygen Optimization in Severe Traumatic Brain Injury Phase-II: A Phase II Randomized Trial; Critical Care Medicine. November 2017 • Volume 45 • Number 11
3. Stiefel, M. F., Spiotta, A., Gracias, V. H., Garuffe, A. M., Guillamondegui, O., Maloney-Wilensky, E., Bloom, S., Grady, M., & LeRoux, P. D. (2005). Reduced mortality rate in patients with severe traumatic brain injury treated with brain tissue oxygen monitoring, Journal of Neurosurgery, 103(5), 805-811. Retrieved Mar 24, 2020, from https://thejns.org/view/journals/j-neurosurg/103/5/article-p805.xml
4. IFU Integra® Licox® PtO2 Monitor, 60904052 Rev. A